BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35459780)

  • 1. CBX3 accelerates the malignant progression of glioblastoma multiforme by stabilizing EGFR expression.
    Peng W; Shi S; Zhong J; Liang H; Hou J; Hu X; Wang F; Zhang J; Geng S; Sun X; Zhong D; Cui H
    Oncogene; 2022 May; 41(22):3051-3063. PubMed ID: 35459780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PUF60 promotes glioblastoma progression through regulation of EGFR stability.
    Wang F; Peng L; Sun Y; Zhang B; Lu S
    Biochem Biophys Res Commun; 2022 Dec; 636(Pt 1):190-196. PubMed ID: 36335869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSN6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR.
    Hou J; Deng Q; Zhou J; Zou J; Zhang Y; Tan P; Zhang W; Cui H
    Oncogene; 2017 Feb; 36(8):1134-1144. PubMed ID: 27546621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ubiquitin ligase SMURF2 enhances epidermal growth factor receptor stability and tyrosine-kinase inhibitor resistance.
    Ray P; Raghunathan K; Ahsan A; Allam US; Shukla S; Basrur V; Veatch S; Lawrence TS; Nyati MK; Ray D
    J Biol Chem; 2020 Sep; 295(36):12661-12673. PubMed ID: 32669362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal Growth Factor (EGF) Augments the Invasive Potential of Human Glioblastoma Multiforme Cells via the Activation of Collaborative EGFR/ROS-Dependent Signaling.
    Pudełek M; Król K; Catapano J; Wróbel T; Czyż J; Ryszawy D
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.
    Shen J; Zhang T; Cheng Z; Zhu N; Wang H; Lin L; Wang Z; Yi H; Hu M
    J Exp Clin Cancer Res; 2018 Jul; 37(1):157. PubMed ID: 30016965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
    Cho J; Pastorino S; Zeng Q; Xu X; Johnson W; Vandenberg S; Verhaak R; Cherniack AD; Watanabe H; Dutt A; Kwon J; Chao YS; Onofrio RC; Chiang D; Yuza Y; Kesari S; Meyerson M
    Cancer Res; 2011 Dec; 71(24):7587-96. PubMed ID: 22001862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of glycosyltransferase PomGnT1 in glioblastoma progression.
    Lan J; Guo P; Lin Y; Mao Q; Guo L; Ge J; Li X; Jiang J; Lin X; Qiu Y
    Neuro Oncol; 2015 Feb; 17(2):211-22. PubMed ID: 25085363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens.
    Pedron S; Wolter GL; Chen JE; Laken SE; Sarkaria JN; Harley BAC
    Biomaterials; 2019 Oct; 219():119371. PubMed ID: 31352310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
    Hu J; Jo M; Cavenee WK; Furnari F; VandenBerg SR; Gonias SL
    Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15984-9. PubMed ID: 21896743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
    Hu L; Shen D; Liang D; Shi J; Song C; Jiang K; Menglin Ren ; Du S; Cheng W; Ma J; Li S; Bi X; Barr MP; Fang Z; Xu Q; Li W; Piao H; Meng S
    Cancer Lett; 2020 Nov; 493():156-166. PubMed ID: 32860853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma.
    Li M; Mukasa A; Inda MM; Zhang J; Chin L; Cavenee W; Furnari F
    J Exp Med; 2011 Dec; 208(13):2657-73. PubMed ID: 22162832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CBX3/HP1γ promotes tumor proliferation and predicts poor survival in hepatocellular carcinoma.
    Zhong X; Kan A; Zhang W; Zhou J; Zhang H; Chen J; Tang S
    Aging (Albany NY); 2019 Aug; 11(15):5483-5497. PubMed ID: 31375643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma.
    Lin DC; Xu L; Chen Y; Yan H; Hazawa M; Doan N; Said JW; Ding LW; Liu LZ; Yang H; Yu S; Kahn M; Yin D; Koeffler HP
    Cancer Res; 2015 May; 75(9):1815-27. PubMed ID: 25877876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells.
    Ramis G; Villalonga-Planells R; Serra-Sitjar M; Brell M; Fernández de Mattos S; Villalonga P
    Cell Oncol (Dordr); 2019 Aug; 42(4):521-536. PubMed ID: 30980364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling.
    Xiao Q; Dong M; Cheng F; Mao F; Zong W; Wu K; Wang H; Xie R; Wang B; Lei T; Guo D
    Int J Oncol; 2018 Sep; 53(3):1069-1082. PubMed ID: 30015847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AKIP1 accelerates glioblastoma progression through stabilizing EGFR expression.
    Wan S; Liu C; Li C; Wang Z; Zhao G; Li J; Ran W; Zhong X; Li Y; Zhang L; Cui H
    Oncogene; 2023 Sep; 42(39):2905-2918. PubMed ID: 37596322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR-induced NF-κB activation.
    Liu X; Yue C; Shi L; Liu G; Cao Q; Shan Q; Wang Y; Chen X; Li H; Wang J; Gao S; Niu M; Yu R
    J Cell Mol Med; 2020 Jul; 24(13):7550-7562. PubMed ID: 32452133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM.
    McKinney A; Lindberg OR; Engler JR; Chen KY; Kumar A; Gong H; Lu KV; Simonds EF; Cloughesy TF; Liau LM; Prados M; Bollen AW; Berger MS; Shieh JTC; James CD; Nicolaides TP; Yong WH; Lai A; Hegi ME; Weiss WA; Phillips JJ
    Mol Cancer Ther; 2019 Sep; 18(9):1565-1576. PubMed ID: 31270152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.